Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma (CERVINO)

Active Date: June 13, 2025

IRB Number: M22-574

Condition/Disease: Multiple Myeloma

Lead Researcher: Joseph Heng, MD

Location: Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield
Nancy Knowles Cancer Center - Elmhurst

Time Commitment: 3-4 years

Status: Accepting Participants

Current Trial Type: Interventional

Phase: III

Contact Name: Jessica Schnase, Mgr Cancer Research

Phone: 630-646-6072

Fax: 630-646-6074

Alternate Phone: 630-646-6073

If you have reached this screen, your current device or browser is unable to access the full Edward-Elmhurst Health Web site.

To see the full site, please upgrade your browser to the most recent version of Safari, Chrome, Firefox or Internet Explorer. If you cannot upgrade your browser, you can remain on this site.